NO20053678D0 - Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser - Google Patents

Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser

Info

Publication number: NO20053678D0
Authority: NO; Norway
Prior art keywords: treatment; combination therapy; inflammatory disorders; immune inflammatory; immune
Prior art date: 2003-02-14

Application number

NO20053678A

Other languages

English (en)

Other versions

NO20053678L (no

Inventor

Edward Roydon Jost-Price

Brendan Smith

Benjamin A Auspitz

Bradley B Brasher

Noah Sachs

Todd W Chappell

Palaniyandi Manivasakam

Original Assignee

Combinatorx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-14

Filing date

2005-07-29

Publication date

2005-07-29

2005-07-29 Application filed by Combinatorx Inc filed Critical Combinatorx Inc

2005-07-29 Publication of NO20053678D0 publication Critical patent/NO20053678D0/no

2005-09-12 Publication of NO20053678L publication Critical patent/NO20053678L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Transplantation (AREA)

NO20053678A 2003-02-14 2005-07-29 Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser NO20053678L (no)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US44764803P	2003-02-14	2003-02-14
US44741203P	2003-02-14	2003-02-14
US44741503P	2003-02-14	2003-02-14
US44755303P	2003-02-14	2003-02-14
US44736603P	2003-02-14	2003-02-14
US46475303P	2003-04-23	2003-04-23
US50302603P	2003-09-15	2003-09-15
PCT/US2004/004077 WO2004073614A2 (en)	2003-02-14	2004-02-12	Combination therapy for the treatment of immunoinflammatory disorders

Publications (2)

Publication Number	Publication Date
NO20053678D0 true NO20053678D0 (no)	2005-07-29
NO20053678L NO20053678L (no)	2005-09-12

Family

ID=32913413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053678A NO20053678L (no)	2003-02-14	2005-07-29	Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser

Country Status (14)

Country	Link
US (1)	US20040224876A1 (no)
EP (1)	EP1599212A4 (no)
JP (1)	JP2006517969A (no)
KR (1)	KR20050110634A (no)
AR (1)	AR043188A1 (no)
AU (1)	AU2004212919A1 (no)
CA (1)	CA2514061A1 (no)
HR (1)	HRP20050804A2 (no)
IS (1)	IS8023A (no)
MX (1)	MXPA05008649A (no)
NO (1)	NO20053678L (no)
PL (1)	PL378108A1 (no)
TW (2)	TW200509958A (no)
WO (1)	WO2004073614A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9812110D0 (en)	1998-06-06	1998-08-05	Levelrecall Limited	Yttrium oxide based gas mantle
US6861056B2 (en) *	2001-06-05	2005-03-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
GB0307864D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
GB0327840D0 (en) *	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
CN101524351A (zh) *	2003-12-01	2009-09-09	沃泰克斯药物股份有限公司	使用ice抑制剂治疗感染疾病
US20070020299A1 (en)	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2348920T3 (es)	2005-04-13	2010-12-17	Astion Development A/S	Agonistas de adrenoceptores beta-2 para el tratamiento de enfermedades del tejido conectivo de la piel.
TW200711649A (en) *	2005-06-17	2007-04-01	Combinatorx Inc	Combination therapy for the treatment of immunoinflammatory disorders
US20060293381A1 (en) *	2005-06-23	2006-12-28	Kaihei Kojima	Fungicidal effect by regulating signal transduction pathways
ITMI20051826A1 (it) *	2005-09-29	2007-03-30	Novachem S A	Kit per la somministrazione parenterale di medicamenti
US20070196421A1 (en) *	2005-10-03	2007-08-23	Hunter William L	Soft tissue implants and drug combination compositions, and use thereof
US20070128289A1 (en) *	2005-12-07	2007-06-07	Zhao Jonathon Z	Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
CN101371141A (zh) *	2006-01-10	2009-02-18	高露洁-棕榄公司	调节细胞表面受体预防或减少炎症的方法
TR201807065T4 (tr)	2006-02-02	2018-06-21	Novartis Ag	Tüberöz sklerozis tedavisi.
AU2011205053B2 (en) *	2006-02-02	2013-02-07	Novartis Ag	Tuberous Sclerosis treatment
US8207188B2 (en) *	2006-04-07	2012-06-26	Michalis Nicolaou	Treatment of diseases modulated by a H4 receptor agonist
WO2008031014A1 (en) *	2006-09-08	2008-03-13	Ore Pharmaceuticals Inc.	Method for reducing or alleviating inflammation in the digestive tract
WO2008100539A1 (en) *	2007-02-12	2008-08-21	Michalis Nicolaou	Treatment of copd, gastro-esophageal reflux disease (gerd), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, lra drugs, anti-h1 and/or anti-h2 drugs
CN101940571A (zh) *	2007-04-13	2011-01-12	南方研究所	抗血管生成剂和使用方法
ES2493641T3 (es) *	2007-06-28	2014-09-12	Cydex Pharmaceuticals, Inc.	Administración nasal de soluciones acuosas de corticosteroides
EP2203168B1 (en) *	2007-09-18	2014-07-16	Stanford University	Compositions for treating a flaviviridae family viral infection
US8940730B2 (en)	2007-09-18	2015-01-27	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions of treating a Flaviviridae family viral infection
US9149463B2 (en) *	2007-09-18	2015-10-06	The Board Of Trustees Of The Leland Standford Junior University	Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) *	2007-09-18	2015-08-11	The Board Of Trustees Of The Leland Stanford Junior University	Methods and composition of treating a flaviviridae family viral infection
US9623000B2 (en)	2008-07-31	2017-04-18	Dekel Pharmaceuticals Ltd	Compositions and methods for treating inflammatory disorders
WO2010107739A2 (en) *	2009-03-18	2010-09-23	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions of treating a flaviviridae family viral infection
RU2526912C2 (ru)	2009-04-01	2014-08-27	Колгейт-Палмолив Компани	Композиции карбонатных соединений, препятствующих образованию биопленки, для использования при уходе за полостью рта
AU2009344336B2 (en)	2009-04-01	2013-07-18	Colgate-Palmolive Company	Menthol-derivative compounds and use thereof as oral and systemic active agents
AR076041A1 (es)	2009-04-01	2011-05-11	Colgate Palmolive Co	Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
TWI405565B (zh)	2009-04-01	2013-08-21	Colgate Palmolive Co	口腔用組成物之抗－骨質流失及抗－牙周附連喪失之功效
KR101388235B1 (ko) *	2011-09-20	2014-04-24	가톨릭대학교 산학협력단	메클리진을 포함하는 관절염 예방 및 치료용 조성물
US10688083B2 (en)	2015-06-30	2020-06-23	Eiger Group International, Inc.	Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
US10765630B2 (en)	2018-03-16	2020-09-08	SEN-JAM Pharmaceutical LLC	Methods and compositions to treat enteropathic arthritis
KR102422449B1 (ko) *	2019-10-18	2022-07-20	연세대학교 산학협력단	결핵 및 비결핵항산균 감염 질환의 예방, 개선 또는 치료용 조성물
KR20230039979A (ko) *	2021-09-15	2023-03-22	서울대학교산학협력단	아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1101104A (en) *	1965-06-02	1968-01-31	Joseph Glasser	Compositions for the treatment of psoriasis
US4444780A (en) *	1982-08-30	1984-04-24	Ortho Pharmaceutical Corporation	Method for treating atopic dermatitis
WO1992008474A2 (en) *	1990-11-20	1992-05-29	The National Heart & Lung Institute	Treatment of lung diseases
WO1996011009A1 (en) *	1994-10-05	1996-04-18	Cari Loder	Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
GB9619631D0 (en) *	1996-09-20	1996-11-06	British Biotech Pharm	Combination therapy
FI104363B (fi) *	1997-05-19	2000-01-14	Timo Kalevi Korpela	Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
US6372234B1 (en) *	1997-05-27	2002-04-16	Sembiosys Genetics Inc.	Products for topical applications comprising oil bodies
AU739261B2 (en) *	1997-07-01	2001-10-11	Pfizer Inc.	Sertraline salts and sustained-release dosage forms of sertraline
IN188720B (no) *	1997-11-06	2002-11-02	Panacea Biotec Ltd
US6140337A (en) *	1997-12-23	2000-10-31	Schering Corporation	Methods for the treatment of mental disorders
US6423721B1 (en) *	1998-09-10	2002-07-23	Schering Corporation	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6492400B1 (en) *	1998-12-18	2002-12-10	Bristol-Myers Squibb Pharma Company	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US20020006961A1 (en) *	1999-05-14	2002-01-17	Katz Stanley E.	Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) *	1999-07-06	2002-05-23	Osbakken Robert S.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
EP1299119A2 (en) *	2000-05-08	2003-04-09	David Haines	Immunosuppressive compositions comprising an immunophilin-binding compound and a ginkgolide compound
DE60142313D1 (de) *	2000-10-02	2010-07-15	Univ Emory	Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
US6599914B2 (en) *	2001-04-24	2003-07-29	Schering Corporation	Inhibition of cytokine generation
US7034059B2 (en) *	2001-07-02	2006-04-25	Sepracor Inc.	Methods of using norfluoxetine
AR041386A1 (es) *	2002-09-24	2005-05-18	Combinatorx Inc	Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
WO2005030132A2 (en) *	2003-09-24	2005-04-07	Combinatorx, Incorporated	Therapeutic regimens for administering drug combinations

2004
- 2004-02-12 AU AU2004212919A patent/AU2004212919A1/en not_active Abandoned
- 2004-02-12 TW TW093103296A patent/TW200509958A/zh unknown
- 2004-02-12 CA CA002514061A patent/CA2514061A1/en not_active Abandoned
- 2004-02-12 US US10/777,518 patent/US20040224876A1/en not_active Abandoned
- 2004-02-12 KR KR1020057015072A patent/KR20050110634A/ko not_active Application Discontinuation
- 2004-02-12 MX MXPA05008649A patent/MXPA05008649A/es unknown
- 2004-02-12 EP EP04710606A patent/EP1599212A4/en not_active Withdrawn
- 2004-02-12 TW TW097127777A patent/TW200902047A/zh unknown
- 2004-02-12 PL PL378108A patent/PL378108A1/pl not_active Application Discontinuation
- 2004-02-12 WO PCT/US2004/004077 patent/WO2004073614A2/en active Application Filing
- 2004-02-12 JP JP2006503514A patent/JP2006517969A/ja not_active Withdrawn
- 2004-02-16 AR ARP040100470A patent/AR043188A1/es unknown
2005
- 2005-07-29 NO NO20053678A patent/NO20053678L/no not_active Application Discontinuation
- 2005-09-13 IS IS8023A patent/IS8023A/is unknown
- 2005-09-13 HR HR20050804A patent/HRP20050804A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2004212919A1 (en)	2004-09-02
EP1599212A2 (en)	2005-11-30
NO20053678L (no)	2005-09-12
HRP20050804A2 (en)	2006-02-28
PL378108A1 (pl)	2006-03-06
CA2514061A1 (en)	2004-09-02
WO2004073614A2 (en)	2004-09-02
WO2004073614A3 (en)	2004-11-11
US20040224876A1 (en)	2004-11-11
JP2006517969A (ja)	2006-08-03
IS8023A (is)	2005-09-13
KR20050110634A (ko)	2005-11-23
MXPA05008649A (es)	2005-11-23
AR043188A1 (es)	2005-07-20
EP1599212A4 (en)	2006-02-08
TW200902047A (en)	2009-01-16
TW200509958A (en)	2005-03-16

Publication	Publication Date	Title
NO20053678D0 (no)	2005-07-29	Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20040097L (no)	2004-03-01	Kombinasjoner for behandling av inflammatoriske forstyrrelser
CY2013022I1 (el)	2020-05-29	Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
NO20043237L (no)	2004-08-02	Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
DK1660057T3 (da)	2012-08-20	Kombinationsterapi til behandling af neovaskulære øjenlidelser
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20044054L (no)	2004-11-24	Administrering av midler for behandling av betennelse
EP1490044A4 (en)	2008-04-16	COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS
IS7941A (is)	2005-07-18	Bensasepínafleiður til að meðhöndla taugasjúkdóma
NO20052894D0 (no)	2005-06-14	4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
ZA200700384B (en)	2008-09-25	Hydantoin derivatives for the treatment of inflammatory disorders
NO20053211D0 (no)	2005-06-30	Forbindelser for behandling av metabolske forstyrrelser.
IS7202A (is)	2004-03-31	Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
IL181706A0 (en)	2007-07-04	The treatment of inflammatory disorders and pain
AU2003228819A8 (en)	2003-11-17	Combinations for the treatment of inflammatory skin disorders
IL162485A0 (en)	2005-11-20	Compounds for the treatment of inflammatory disorders
CY2018006I1 (el)	2018-06-27	Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
ITMI20031311A0 (it)	2003-06-27	Formulazioni per il trattamento di disturbi artrosici
EP1611120A4 (en)	2008-04-23	NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DK1487828T3 (da)	2009-02-02	Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
NO20055098D0 (no)	2005-11-01	Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
NO20043445L (no)	2004-08-18	Kombinasjonsterapi for behandling av bakterielle infeksjoner
ZA200505996B (en)	2006-12-27	Combination therapy for the treatment of immunoinflammatory disorders
NO20033160D0 (no)	2003-07-10	Anordning for behandling av gravann
NO20042166L (no)	2004-05-25	Kombinasjonsterapi for behandling av sykdom

Legal Events

Date	Code	Title	Description
2009-10-05	FC2A	Withdrawal, rejection or dismissal of laid open patent application